PVX108 – Discover Pharma

Welcome to Discover Pharma! Today is : November 13, 2026

PVX108

Research & Development,Therapeutic Areas
Aravax reports positive Phase 2 results for peanut allergy immunotherapy
Aravax’s PVX108 immunotherapy met its primary endpoint in a Phase [...]
November 13, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Aravax to present Phase 2 peanut allergy data in November
Aravax will present topline Phase 2 clinical trial results for [...]
October 5, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Aravax’s PVX108 wins FDA Fast Track designation for peanut allergy
Aravax’s PVX108 has received FDA Fast Track designation as the [...]
August 3, 2026
Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas
Aravax adds allergy specialists to board as peanut therapy advances
Aravax has appointed two senior industry figures to its board [...]
May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.